sar425899 dual agonist glp-1 glucagon sanofi in type 2 diabetes: Friend or foe? - Caruso - 2023 - Diabetes/Metabolism Research and Reviews GLP-1 medications, or glucagon-like peptide-1

A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea

27 In the pancreas, GLP-1 receptor (GLP-1R) activation in islet cells promotes glucose-dependent insulin secretion from -cells, 28 inhibits glucagon release from -cells, and suppresses exocrine function via induction of pancreatic somatostatin

While there is potential mechanistic overlap with DPP-4 inhibitors or dual GLP/GIP receptor agonists we focus the current review on GLP-1RAs due to preponderance and availability of longer-term data, as well as the significantly higher market penetrance of this drug class

The direct action of GIP on its receptor, which is expressed by these cells, is what causes GIP stimulation to increase glucagon secretion by alpha cells in contrast to GLP- 1 [72,73,74]

If I call, I get an immediate answer from a real person